Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

7,980 public trials 715 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

NCT01524770

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Daytona Beach, Florida, United States
View Trial Details
Completed

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus

NCT01584232

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Aichi, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ehime, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Fukuoka, Japan
View all 15 locations
View Trial Details
Completed

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

NCT01183013

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1264.3.01026 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1264.3.01021 Boehringer Ingelheim Investigational Site Montgomery, Alabama, United States
  • 1264.3.01020 Boehringer Ingelheim Investigational Site Muscle Shoals, Alabama, United States
  • 1264.3.01062 Boehringer Ingelheim Investigational Site Chandler, Arizona, United States
View all 132 locations
View Trial Details
Completed

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

NCT01451398

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
Locations
  • Anaheim, California, United States
  • Huntington Beach, California, United States
  • Laguna Hills, California, United States
  • Long Beach, California, United States
View all 76 locations
View Trial Details
Completed

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

NCT00332488

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • Radiant Research-Birmingham Birmingham, Alabama, United States
  • Parkway Medical Center Birmingham, Alabama, United States
  • Redpoint Research Phoenix, Arizona, United States
  • Arizona Center for Clinical Research Phoenix, Arizona, United States
View all 120 locations
View Trial Details
Completed

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Type 2, +4 more
Locations
  • Coastal Clinical Research Inc Mobile, Alabama, United States
  • Quality of Life Medical & Research Center Tucson, Arizona, United States
  • Southern Arizona VA Healthcare System Tucson, Arizona, United States
  • Tucson Clinical Research Tucson, Arizona, United States
View all 151 locations
View Trial Details
Completed

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

NCT00754624

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
Locations
  • Dorothy L & James E Frank Diabetes Research Institute San Mateo, California, United States
  • Sansum Medical Research Institute Santa Barbara, California, United States
  • Alliance Medical Group of Greater Waterbury Middlebury, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
View all 40 locations
View Trial Details
Completed

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

NCT00308737

Conditions
Autoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1, +8 more
Locations
  • Southwest Health Ltd Research Division Phoenix, Arizona, United States
  • Lovelace Scientific Resources Phoenix, Arizona, United States
  • Northwest Medical Center Phoenix, Arizona, United States
  • Arizona Center for Clinical Research Phoenix, Arizona, United States
View all 176 locations
View Trial Details

Related conditions